News
Hosted on MSN7mon
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTechThere are no approved vaccines for HSV, and GSK’s decision to stop developing ... an investigational vaccine for herpes simplex virus type 2. The candidate is currently in phase 1/2 trial ...
GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.
Hosted on MSN4mon
It’s rarely lethal, but genital herpes costs the world $35 billion a year and 20% of people have itSymptomatic HSV-2 infection is also associated with an ... and therapeutics that reduce severity and viral load. Another company, GSK, completed a vaccine trial in September 2024, but the vaccine ...
Two earlier trials demonstrated that a vaccine based on the HSV-2 glycoprotein D subunit (gD-2) was effective in protecting HSV-1/HSV-2-seronegative women whose sexual partners had recurrent HSV ...
The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...
GlaxoSmithKline’s last act of 2019 was the completion of its near-€1 billion deal to divest two vaccines to Bavarian Nordic. It’s another piece of the transformation put in place by chief ...
GSK is also working with SK Bioscience on a phase 1/2 study for a vaccine based on self-assembling nanoparticle technology developed by the University of Washington, with funding from CEPI and the ...
British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...
(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results